Condition
Multidrug-Resistant Tuberculosis
Total Trials
6
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
3 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (2)
P 4 (1)
Trial Status
Completed4
Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07393438Phase 2Not Yet RecruitingPrimary
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
NCT04260477Phase 3RecruitingPrimary
Novel Triple-dose Tuberculosis Retreatment Regimen
NCT02727582CompletedPrimary
Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment
NCT01424670Phase 3CompletedPrimary
Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
NCT02984579CompletedPrimary
Line Probe Assay Evaluation Study
NCT01521364Phase 4CompletedPrimary
Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Showing all 6 trials